NHS cancer patients denied life-saving drugs due to Brexit costs, report finds

**The UK faces a dilemma where life-saving cancer drugs are being denied due to Brexit's extra costs and red tape.** Rising drug import prices, increased bureaucracy, and delays in clinical trials have hit UK patients hard, particularly children with cancer who are stuck without access to essential treatments. The government is working to strengthen ties with the EU on research but faces significant challenges as ongoing red tape hinders progress, necessitating further cooperation to avoid further delays.